AI Science Tracker
EN

Development and validation of a prognostic model and risk calculator for the estimation of bipolar-spectrum disorder risk in hospitalised adolescents with non-psychotic/non-bipolar mental disorders

Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; Child and Adolescent Mental Health Services, South London and Maudsley NHS Foundation Trust, London, UK; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health. Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain; IMARD Group, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; Biomedical Research Networking Centre Consortium on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Department of Medicine, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain; Centre for Affective Disorders (CfAD), Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK; South London and Maudsley NHS Foundation Trust, London, UK; Hospital Universitario La Paz, IdiPAZ, School of Medicine Universidad Autónoma de Madrid, CIBERSAM, Madrid, Spain; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; School of Medicine, University College Dublin, Dublin, Ireland; University of Oulu, Faculty of Medicine, Oulu, Finland; St John of God Hospitaller Services Group, Hospitaller House, Stillorgan, Dublin, Ireland; Academic Psychiatry, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; National Specialist Adolescent Mood disorders Service (NSAMS), Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; SCIENCES lab, Department of Psychiatry, University of Ottawa, Department of Psychiatry, Ottawa, ON, Canada; Regional Centre for the Treatment of Eating Disorders and On Track: The Champlain First Episode Psychosis Program, Department of Mental Health, The Ottawa Hospital, Ottawa, ON, Canada; Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program University of Ottawa, Ottawa, ON, Canada; Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; OASIS Service, South London and Maudsley NHS Foundation Trust, London, UK; National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK; Department of Psychiatry, Hospital del Mar, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/ Northwell, Hempstead, NY, USA; Institute of Behavioral Science, The Feinstein Institutes for Medical Research, Manhasset, NY, USA · 29 Sep 2025 · medicine

Discovery

Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; Child and Adolescent Mental Health Services, South London and Maudsley NHS Foundation Trust, London, UK; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health. Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain; IMARD Group, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; Biomedical Research Networking Centre Consortium on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Department of Medicine, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain; Centre for Affective Disorders (CfAD), Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK; South London and Maudsley NHS Foundation Trust, London, UK; Hospital Universitario La Paz, IdiPAZ, School of Medicine Universidad Autónoma de Madrid, CIBERSAM, Madrid, Spain; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; School of Medicine, University College Dublin, Dublin, Ireland; University of Oulu, Faculty of Medicine, Oulu, Finland; St John of God Hospitaller Services Group, Hospitaller House, Stillorgan, Dublin, Ireland; Academic Psychiatry, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; National Specialist Adolescent Mood disorders Service (NSAMS), Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; SCIENCES lab, Department of Psychiatry, University of Ottawa, Department of Psychiatry, Ottawa, ON, Canada; Regional Centre for the Treatment of Eating Disorders and On Track: The Champlain First Episode Psychosis Program, Department of Mental Health, The Ottawa Hospital, Ottawa, ON, Canada; Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program University of Ottawa, Ottawa, ON, Canada; Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; OASIS Service, South London and Maudsley NHS Foundation Trust, London, UK; National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK; Department of Psychiatry, Hospital del Mar, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/ Northwell, Hempstead, NY, USA; Institute of Behavioral Science, The Feinstein Institutes for Medical Research, Manhasset, NY, USA

Development and validation of a prognostic model and risk calculator for the estimation of bipolar-spectrum disorder risk in hospitalised adolescents with non-psychotic/non-bipolar mental disorders

Source check: Source checked. Not independent scientific confirmation.

Finding: Among 105 hospitalized adolescents followed longitudinally, 18 developed bipolar-spectrum disorder; the model identified mania-like symptom variables associated with onset and reported estimated risk through four years, with discrimination peaking around month 20. Leave-one-out cross-validation (AUC 0.72 at month 20) and bootstrap out-of-bag validation (AUC up to 0.86). This is internal validation in a small cohort with 18 transitions; external and outpatient validation are absent, and attrition limits generalizability.

Technology: Lasso-Cox machine-learning analysis uses baseline clinical and prodromal symptom characteristics from a prospective adolescent cohort to estimate risk of later bipolar-spectrum disorder.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Lasso-Cox machine-learning analysis uses baseline clinical and prodromal symptom characteristics from a prospective adolescent cohort to estimate risk of later bipolar-spectrum disorder.
Test and result
Among 105 hospitalized adolescents followed longitudinally, 18 developed bipolar-spectrum disorder; the model identified mania-like symptom variables associated with onset and reported estimated risk through four years, with discrimination peaking around month 20.
Limitation / still unknown
Leave-one-out cross-validation (AUC 0.72 at month 20) and bootstrap out-of-bag validation (AUC up to 0.86). This is internal validation in a small cohort with 18 transitions; external and outpatient validation are absent, and attrition limits generalizability.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12916283/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary source full text Methods and Results; version/date checked against bibliographic record..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.